Log In
BCIQ
Print this Print this
 

ralfinamide

Also known as: NW-1029

  Manage Alerts
Collapse Summary General Information
Company Newron Pharmaceuticals S.p.A.
DescriptionAlpha-aminoamide sodium (Na) channel blocker
Molecular Target Sodium channel ; NMDA receptor
Mechanism of ActionCalcium channel blocker; Na channel blocker; NMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat inflammatory pain; Treat neuropathic chronic pain; Treat neuropathic low back pain; Treat pain; Treat post-dental surgery pain
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$59.8M

0

$9.6M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/03/2011

$59.8M

0

$9.6M

Get a free BioCentury trial today